---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-264916"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2026-06-10T11:32:05+00:00"
generated_at: "2026-06-10T11:35:42.463225+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Cullinan Therapeutics reports positive clinical data for CLN-978 and velinotamig in autoimmune diseases

## Summary
- CLN-978 achieved DAS28-ESR remission in a rituximab-refractory RA patient, reducing score from 4.0 to 2.2 at week 4.
- First three SLE patients on CLN-978 multi-dose showed safety consistent with EULAR 2026 data; rapid proteinuria improvement supports lupus nephritis trial.
- Velinotamig (BCMA TCE) induced complete renal responses in two SLE patients; SLEDAI-2K scores dropped to 0 and 2 at week 8.
- Cullinan plans Phase 2a expansion for CLN-978 in lupus nephritis in early 2027 and Phase 1/2a for velinotamig in autoimmune cytopenias in Q1 2027.

## SEC filing metadata
- accession: 0001193125-26-264916
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2026-06-10T11:32:05+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000119312526264916/0001193125-26-264916-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000119312526264916/cgem-20260610.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-264916
- JSON: https://secwatch.observer/filing/0001193125-26-264916.json
- Plain text: https://secwatch.observer/filing/0001193125-26-264916.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.